CSIMarket Company Name, Ticker, Industry, else..
 
Cymabay Therapeutics Inc   (NASDAQ: CBAY)
Other Ticker:  
 
 
Price: $32.4800 $0.01 0.031%
Day's High: $32.5 Week Perf: 0.09 %
Day's Low: $ 32.48 30 Day Perf: 0.9 %
Volume (M): 8,356 52 Wk High: $ 0.00
Volume (M$): $ 271,409 52 Wk Avg: $0.00
Open: $32.49 52 Wk Low: $0.00



 Market Capitalization (Millions $) 3,457
 Shares Outstanding (Millions) 106
 Employees 68
 Revenues (TTM) (Millions $) 31
 Net Income (TTM) (Millions $) -105
 Cash Flow (TTM) (Millions $) 187
 Capital Exp. (TTM) (Millions $) 0

Cymabay Therapeutics Inc
Cymabay Therapeutics Inc is a biopharmaceutical company founded in 1988 and based in Newark, California. The company focuses on the development of therapies for liver and metabolic diseases.

Cymabay's lead product candidate is seladelpar, a potent and selective partial agonist of the peroxisome proliferator-activated receptor delta (PPARd), which is being developed for the treatment of primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and other liver diseases. PPARd is a nuclear receptor that plays a crucial role in regulating lipid and glucose metabolism, inflammation, and fibrosis in the liver.

Seladelpar has been shown to have a strong therapeutic effect in preclinical and clinical studies, demonstrating a reduction in liver injury, fibrosis, inflammation, and improvement in metabolic parameters. Cymabay is currently conducting several clinical trials to evaluate the safety and efficacy of Seladelpar in patients with PBC and NASH.

Besides seladelpar, Cymabay has a diverse pipeline of preclinical and clinical product candidates focusing on liver and metabolic diseases. These include a potent FXR agonist for the treatment of NASH and other liver diseases, an acyl-CoA synthetase inhibitor for the treatment of metabolic diseases, and a GPR139 antagonist for the treatment of schizophrenia and neuroinflammatory disorders.

Cymabay has collaborations with leading academic institutions and pharmaceutical companies to accelerate the development of its product candidates and expand its scientific knowledge. Additionally, the company has a strong intellectual property portfolio with a focus on composition of matter, methods of use, and formulation patents.

Cymabay's strategy is to bring innovative treatments to patients in need, leverage its scientific expertise and collaborations, and build a sustainable, successful biopharmaceutical company.


   Company Address: 7601 Dumbarton Circle Fremont 94555 CA
   Company Phone Number: 293-8800   Stock Exchange / Ticker: NASDAQ CBAY


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IRWD   -4.58%    
MIRM   -0.74%    
NGM   -3.14%    
RDHL   -7.61%    
REGN   -3.39%    
VRTX   -0.13%    
• View Complete Report
   



Management Announcement

CymaBay Announces European Medicines Agency Accepts Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

Published Mon, Mar 4 2024 1:00 PM UTC


CymaBay Therapeutics Inc (Nasdaq: CBAY) has recently announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Seladelpar, a potential treatment for Primary Biliary Cholangitis (PBC). This comes after the company submitted applications for Seladelpar to the United Kingdom Medicines and Healthcare products Regulator...
Cymabay Therapeutics Inc

CymaBay Therapeutics Inc. Reports Revenue of $0.057 Million Despite Net Deficit in Q4 2023

CymaBay Therapeutics Inc, a major player in the pharmaceutical preparations industry, has been making significant strides in recent months. Despite facing a net deficit of $41.902 million in the fourth quarter of 2023, larger than the previous year's $26.633 million net deficit, the company has managed to stay afloat and make progress towards its goals.
In terms of revenue, CymaBay reported $0.057 million in the fourth quarter of 2023, along with a shortfall of $105.37 million for the financial year. While these numbers may seem concerning, it's important to consider the context. The company has been actively working to improve its financial standing, evident from its decision to grant inducement awards to three employees in February 2024. This move demonstrates CymaBay's commitment to attracting and retaining top talent, which can positively impact the company's future results.
Shares

CymaBay Therapeutics Rises with Inducement Grants and Public Offering Success

Published Tue, Feb 20 2024 9:05 PM UTC

CymaBay Therapeutics Continues to Make Strides with Inducement Grants and Public Offering
In a recent press release, CymaBay Therapeutics, Inc. announced the grant of inducement awards to three employees on February 16, 2024, in connection with their commencement of employment at the company. This move comes after the company previously granted awards to four employees i...
Shares

CymaBay Thrives with $225 Million Public Offering and Inducement Grants for New Employees

Published Mon, Dec 18 2023 9:05 PM UTC

CymaBay Therapeutics, a renowned clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases, recently announced the grant of inducement awards to four employees in accordance with Nasdaq Listing Rule 5635(c)(4). The company approved the grant of non-qualified stock options, allowing the employees to purchase an aggregate of ...
Cymabay Therapeutics Inc

CymaBay Therapeutics Inc Struggles with Increasing Deficits in Q3 2023

Exciting Developments in the Pharmaceutical Industry: CymaBay Therapeutics Inc Raises $225 Million
In the fast-paced and ever-evolving world of the stock market, it is crucial to keep an eye on the bellwethers in major industries. However, amidst the hustle and bustle, it is easy to miss some hidden gems that are making significant strides. CymaBay Therapeutics Inc, a promising player in the Major Pharmaceutical Preparations industry, has recently published its financial results for the third quarter of 2023. While the operating deficit of $-32.207 million may seem concerning, it is essential to look back and put their performance into perspective.
Comparing their recent results with the third quarter of 2022, where CymaBay reported an operating deficit of $-21.363 million, we can observe an increase in the deficit. This recent time-frame from July to September 30, 2023, revealed a notable widening of the shortfall to $-33.882 million. Despite the missing top-line information, these figures indicate that CymaBay Therapeutics Inc has been facing some challenges.
However, it is not all doom and gloom for this innovative entity. Investors and experts are eagerly anticipating the company's next financial update, which is scheduled for November 13, 2023. This will provide a more comprehensive overview of their recent performance and shed light on the steps they have taken to address the current deficits.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com